NLRP1 variant M1184V decreases inflammasome activation in the context of DPP9 inhibition and asthma severity.

Journal Information

Full Title: J Allergy Clin Immunol

Abbreviation: J Allergy Clin Immunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"genotype data for gala ii study participants are available on dbgap under accession number phs001274 and genotype data for sage ii study participants are available on dryad ( https://datadryad org/stash/share/20ma3ithxrak5sxbtnhgpomgednjvftpxdixecth2is ). genotype data for gala ii study participants are available on dbgap under accession number phs001274 and genotype data for sage ii study participants are available on dryad ( https://datadryad org/stash/share/20ma3ithxrak5sxbtnhgpomgednjvftpxdixecth2is )."

Code Sharing
Evidence found in paper:

"Disclosure of potential conflict of interest: M. Geyer receives funding from IFM Therapeutics. S. L. Masters receives funding from Glaxosmithkline and IFM Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest."

Evidence found in paper:

"We thank R. Crawley and S. Russo for outstanding animal husbandry. We also acknowledge the Trans-Omics in Precision Medicine (TOPMed) program imputation panel (freeze 5) supported by the 10.13039/100000050National Heart, Lung, and Blood Institute accessed through the Michigan Imputation Server. The panel was constructed and implemented by the TOPMed Informatics Research Center at the University of Michigan (3R01HL-117626-02S1; contract HHSN268201800002I). The TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract HHSN268201800001I) provided additional data management, sample identity checks, and overall program coordination and support. The Graphical Abstract was prepared using Biorender. We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. This work was supported by Australian National Health and Medical Research Council project grants (grant nos. 1057815, 1099262, 1079187, 1175134, and 1120252) and fellowships (S.L.M. and P.M.H.), fellowships from the Victorian Endowment for Science Knowledge and Innovation (S.L.M.), HHMI-Wellcome International Research Scholarship (S.L.M.), the Sylvia and Charles Viertel Foundation (S.L.M.), the National Health and Medical Research Council Early Career Fellowship (grant no. GNT1143412 to S.D.), the WEHI Centenary Fellowship (C.-H.Y.), and Ormond College’s Thwaites Gutch Fellowship in Physiology (C.-H.Y.). J.M. is funded by the Deutsche Forschungsgemeinschaft (DFG [German Research Foundation] grant no. GRK 2168). This work was also supported in part by the 10.13039/100002330Severns Family Foundation, the 10.13039/100008925American Asthma Foundation (E.G.B.), the RWJF Amos Medical Faculty Development Program (E.G.B.), Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II (E.G.B.), the 10.13039/100000050National Heart, Lung, and Blood Institute (grant nos. R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, and R01HL141845 to E.G.B.), the National Heart, Lung, and Blood Institute Early Career Development Award (grant no. K01 HL140218-03 to M.J.W.), the National Institute of Health and Environmental Health Sciences (grant nos. R01ES015794 and R21ES24844 to E.G.B.), the 10.13039/100006545National Institute on Minority Health and Health Disparities (grant nos. P60MD006902, RL5GM118984, R01MD010443, and R56MD013312 to E.G.B.), the 10.13039/100000051National Human Genome Research Institute (grant no. U01HG009080 to E.G.B.), 10.13039/501100003977ISF (grant nos. 1416/15 and 818/18 to M.G.), 10.13039/100001448Alpha-1 Foundation (grant no. 615533 to M.G.), and the Recanati Foundation (M.G.). Ma.G. is funded by the DFG under Germany’s Excellence Strategy (grant no. EXC2151 – 390873048). J.P.T. was funded by the 10.13039/100000002National Institutes of Health (grant nos. U19-AI-077437 and AI029564) and the 10.13039/100008925American Asthma Foundation/10.13039/100007100Sandler Foundation. Disclosure of potential conflict of interest: M. Geyer receives funding from IFM Therapeutics. S. L. Masters receives funding from Glaxosmithkline and IFM Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025